Infection Tied to One-Fourth of Deaths With Lower-Risk Myelodysplastic Syndromes

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 22, 2025.

By Lori Solomon HealthDay Reporter

TUESDAY, April 22, 2025 -- Roughly one in 14 people with lower-risk myelodysplastic syndromes (LR-MDS) have an infection in the first year after diagnosis, according to a study published online April 10 in Haematologica.

Bente Houtman, from Radboud University Medical Center in Nijmegen, Netherlands, and colleagues investigated the prevalence and risk factors for infections and infection-related death in patients with LR-MDS. The analysis included data from 2,552 patients identified from the European MDS Registry.

The researchers found that the prevalence of infections was 7.6 percent in the first year of follow-up. Nearly one-quarter of all deaths (24.6 percent) were due to infections. There was an independent association between an increased risk for infections and hemoglobin level <8 g/dL, platelet count <50x109/L, absolute neutrophil count <0.8x109/L, cytogenetics intermediate/poor/very poor, and having received red blood cell transfusions at baseline. There was also an independent association for an increased risk for infection-related death with older age at diagnosis, hemoglobin level <8 g/dL, and platelet count <50x109/L.

"Patients with an increased risk of infections could benefit from close monitoring, especially in the first months after diagnosis," the authors write. "Future research should focus on the causality and severity of infections and risk factors over time, to provide more guidance for monitoring."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-23 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords